Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 3/20 | 0.81 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.81 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.81 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.81 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.81 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8509647 | 0.90 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8513779 | 0.90 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9229193 | 0.90 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL10236670 | 0.88 | PSEN1 (0.95) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL10236666 | 0.88 | PSEN1 (0.95) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL721328 | 0.88 | PSEN1 (0.95) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL10236610 | 0.85 | PSEN1 (0.92) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7914890 | 0.85 | PSEN1 (0.92) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL721969 | 0.85 | PSEN1 (0.92) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL237158 | 0.85 | PSEN1 (0.79) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010098495-A1 | IMIDAZOLYLPYRAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |